MYOM2 and Miyoshi myopathy: More sensitive techniques exist to monitor minimal residual disease (MRD) in MM, such as flow cytometry and next generation sequencing, but all of these require invasive bone marrow sampling.6 With mass spectrometry (MS), it is possible to monitor M-proteins in blood in a more sensitive manner than with SPEP.7-9